Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes

Authors: Sarah A MacLeish, Korey K Hood, William H Polonsky, Jamie R Wood, Bruce W Bode, Gregory P Forlenza, Lori M Laffel, Bruce A Buckingham, Amy B Criego, Melissa J Schoelwer, Daniel J DeSalvo, Jennifer L Sherr, David W Hansen, Lindsey R Conroy, Lauren M Huyett, Todd E Vienneau, Trang T Ly; Omnipod 5 in Preschoolers Study Group

Abstract

Aim: Automated insulin delivery (AID) systems have demonstrated improved glycaemic outcomes in people with type 1 diabetes (T1D), yet limited data exist on these systems in very young children and their impact on caregivers. We evaluated psychosocial outcomes following use of the tubeless Omnipod® 5 AID System in caregivers of very young children.

Materials and methods: This 3-month single-arm, multicentre, pivotal clinical trial enrolled 80 children aged 2.0-5.9 years with T1D to use the Omnipod 5 AID System. Caregivers completed questionnaires assessing psychosocial outcomes-diabetes distress (Problem Areas in Diabetes), hypoglycaemia confidence (Hypoglycemia Confidence Scale), well-being (World Health Organization 5 Well-Being Index), sleep quality (Pittsburgh Sleep Quality Index), insulin delivery satisfaction (Insulin Delivery Satisfaction Survey) and system usability (System Usability Scale) at baseline with standard therapy and after 3 months of AID use.

Results: Following 3 months of Omnipod 5 use, caregivers experienced significant improvements across all measures, including diabetes-related psychosocial outcomes (Problem Areas in Diabetes; p < 0.0001, Hypoglycemia Confidence Scale; p < 0.01), well-being (World Health Organization 5 Well-Being Index; p < 0.0001) and perceived system usability (System Usability Scale; p < 0.0001). Significant improvements were seen in the Pittsburgh Sleep Quality Index total score and the overall sleep quality, sleep duration and efficiency subscales (all p < 0.05). Insulin Delivery Satisfaction Survey scores improved on all subscales (greater satisfaction, reduced burden and reduced inconvenience; all p < 0.0001).

Conclusions: Caregivers face unique challenges when managing T1D in very young children. While glycaemic metrics have unquestioned importance, these results evaluating psychosocial outcomes reveal additional meaningful benefits and suggest that the Omnipod 5 AID System alleviates some of the burdens caregivers face with diabetes management.

Source: https://pubmed.ncbi.nlm.nih.gov/39300963/

Share the Post:

BDI Monthly Events

May 7OMEGA Conference
May 7: As a keynote speaker at OMEGA, the First International Conference on Once-Weekly Glycated Albumin Monitoring for Diabetes, Dr. Polonsky (BDI President) will be presenting on “Glucose Monitoring and Behavior Change” (Tokyo, Japan).
May 14Case Consultation
May 14: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
May 18T1D Meet Up
May 18: Time for another T1D meet-up! Our friends and colleagues at GrownupT1Ds, a wonderful nonprofit here in southern California, is organizing another fun social event for adults with type 1 diabetes. This time it is a Walk, Talk & Picnic, and it begins at 11 am at the Bommer Canyon Trail (1 Sunnyhill, Irvine, CA). 92084. This event is free, but please RSVP Kelly Daes at www.grownupt1ds.org.
May 23SITEC 2025
May 23: Dr. Polonsky will be presenting (virtually) on “Far Beyond Time in Range: Exploring the Promises and Limitations of CGM” at SITEC 2025, Innovation and Technology Transforming Diabetes Care (Sao Paolo, Brazil). https://sitec.diabetes.org.br/